SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Badger Meter amended and extended its $150 million revolving credit facility, with a new maturity date of July 8, 2031. The amendment represents a material refinancing and extension of the company's existing credit facilities, affecting its capital structure and liquidity position.
View raw filing on EDGAR →General Motors Financial Company closed a $1 billion public offering of senior notes due 2031 with net proceeds of approximately $993 million. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy—it is neither a merger/acquisition (ma_activity), a dilutive equity issuance (dilutive_issuance), nor a debt covenant breach (covenant_breach). The disclosure is a routine debt offering, which is material to investors but lacks the specific event-type indicators that would classify it as earnings_release, going_concern, or other defined categories.
View raw filing on EDGAR →CarMax Select Receivables Trust 2026-B entered into an Underwriting Agreement on June 9, 2026 for the issuance of approximately $570 million in Asset-backed Notes backed by motor vehicle retail installment sale contracts. This material securitization financing transaction involved the creation and sale of securitized receivables through multiple transaction documents, constituting a significant capital event for the trust.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte & Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst & Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.
View raw filing on EDGAR →This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →Gladstone Investment Corporation entered into Amendment No. 13 to its credit facility on June 10, 2026, materially restructuring the debt arrangement by extending the revolving period to June 8, 2029, increasing the facility size from $300 million to $405 million (with ability to reach $500 million), and modifying interest rate terms and covenants. This material modification to the company's capital structure and financing arrangements affects investor assessment of liquidity and leverage.
View raw filing on EDGAR →Western Digital entered into exchange agreements to swap 1,038,681 shares of SanDisk stock for shares of its own common stock held by institutional investors. This constitutes a material disposition of a significant equity stake (over 1 million shares) in a subsidiary/affiliate, which qualifies as M&A activity under Item 1.01/2.01 framework. The transaction involves a material change in the company's asset composition and shareholder base.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Heritage Insurance Holdings' annual meeting of stockholders held on June 10, 2026. The section presents results for four proposals: election of six directors, ratification of Plante & Moran as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. These are routine shareholder meeting outcomes that materially inform investors about governance and board composition.
View raw filing on EDGAR →Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share, concurrent with the Company's IPO on June 11, 2026. The unregistered private placement under Section 4(a)(2) and Regulation D includes piggyback registration rights for Regeneron and dilutes existing shareholders' ownership.
View raw filing on EDGAR →Alphatec held its June 10, 2026 Annual Meeting of Stockholders, at which shareholders voted on five proposals: election of seven directors, ratification of Deloitte & Touche LLP as auditor, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing reports final voting tallies for three proposals: election of three directors (Chris Cain, Arlene Morris, and Todd Shegog), ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed. This is a material event as it confirms the composition of the board and auditor selection, both of which affect investor assessment of governance and financial oversight.
View raw filing on EDGAR →Universal Health Realty Income Trust granted restricted stock awards to four named executive officers on June 10, 2026, with specified share quantities and vesting terms as part of the company's annual long-term incentive compensation program.
View raw filing on EDGAR →Shareholders of Universal Health Realty Income Trust voted at the June 10, 2026 Annual Meeting on three proposals: election of two Class I trustees (Alan B. Miller and Robert F. McCadden), a nonbinding advisory vote on named executive officer compensation, and ratification of KPMG, LLP as independent auditor.
View raw filing on EDGAR →Alphabet Inc. held its 2026 Annual Meeting of Shareholders on June 5, 2026, with voting results disclosed for fourteen proposals including director elections (Larry Page, Sergey Brin, Sundar Pichai, and others), ratification of Ernst & Young LLP as auditor, approval of stock plan amendments, advisory vote on executive compensation, and multiple shareholder proposals.
View raw filing on EDGAR →Ciena closed a $2.875 billion private offering of convertible senior notes on June 11, 2026, receiving net proceeds of approximately $2.72 billion. The company used proceeds to repay $1.14 billion of existing debt and repurchase shares, representing a significant capital structure and financing transaction.
View raw filing on EDGAR →Ciena sold convertible senior notes and warrants in unregistered transactions under Section 4(a)(2) and Rule 144A, with up to 7,700,978 shares of common stock issuable upon exercise of the warrants. The offering included convertible note hedge and warrant transactions, creating material share dilution.
View raw filing on EDGAR →Dana entered into definitive agreements with Eaton Corporation for a Reverse Morris Trust transaction involving a restructuring, distribution of SpinCo (Eaton's Vehicle and eMobility business), and merger of Dana into SpinCo, resulting in Dana becoming a wholly-owned subsidiary of SpinCo. This is a material change of control transaction unanimously approved by both boards, with former Dana shareholders owning approximately 49.9% of the combined entity post-closing. The transaction involves substantial asset transfers, a $1.1 billion cash payment, and $2.6 billion in bridge financing.
View raw filing on EDGAR →Jade Biosciences held its 2026 Annual Meeting of Stockholders with voting results on the election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers.
View raw filing on EDGAR →The filing's primary focus is the approval of cash retention payments and amended "Change in Control" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.
View raw filing on EDGAR →Mr. Philip R. Martens retired from his positions as member and Chairman of the Board effective June 11, 2026. While the filing also discloses Mr. Venturelli's election as Chairman, the principal disclosed action centers on Martens' departure from the chairmanship—a material executive transition at the board level. The retirement of a sitting Chairman is a material event affecting corporate governance and investor assessment of the company.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Aura Biosciences' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for two proposals: election of two Class II directors (David Johnson and Teresa Marie Bitetti) and ratification of Ernst & Young LLP as the independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are characteristic of Item 5.07 disclosures and are material to investors as they confirm governance decisions and auditor appointment.
View raw filing on EDGAR →Daniel Durn was appointed as Chief Financial Officer and Executive Vice President of Marvell Technology effective June 15, 2026, with a compensation package including $850,000 base salary, $1,000,000 sign-on bonus, and approximately 103,508 RSUs in equity grants.
View raw filing on EDGAR →Legence Corp. held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on five proposals: election of Class I directors (David Coghlan and Bilal Khan), advisory approval of 2026 named executive officer compensation, frequency of future advisory compensation votes (approved for annual frequency), approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Korro Bio's 2026 annual meeting of stockholders held on June 10, 2026, including: (1) election of two Class I directors (Nessan Bermingham and Rachel Meyers) for three-year terms; (2) non-binding advisory approval of named executive officer compensation; and (3) ratification of Ernst & Young LLP as independent auditor. These are routine but material shareholder vote outcomes that affect board composition and governance.
View raw filing on EDGAR →Allbirds increased the maximum aggregate offering price under its at-the-market (ATM) offering program by $48.1 million of Class A common stock on June 11, 2026. This is a registered equity issuance program that will dilute existing shareholders and represents a material capital-raising activity. The filing explicitly references the prospectus supplement and registration statement, confirming this is a formal dilutive equity offering.
View raw filing on EDGAR →IQVIA completed issuance of €950 million in senior notes on June 11, 2026, pursuant to a definitive indenture agreement. The proceeds are being used to refinance existing indebtedness, representing a material capital structure and debt financing event.
View raw filing on EDGAR →Qwest settled exchange offers on June 11, 2026, issuing approximately $1.38 billion in aggregate principal amount of new notes (6.500% Notes due 2051 and 6.750% Notes due 2052) in exchange for outstanding old notes, with consent solicitations to amend existing indentures. This represents a material debt restructuring transaction that affects the company's capital structure and financial obligations, warranting classification as a material activity involving a significant refinancing/exchange of securities.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from Nkarta's June 10, 2026 annual meeting. The filing reports the outcomes of four distinct votes: election of two Class III directors (Ali Behbahani and Zachary Scheiner), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and an advisory vote on the frequency of future compensation votes. These are routine but material governance matters that inform investors of shareholder decisions.
View raw filing on EDGAR →The filing discloses the dismissal of Baker Tilly US, LLP as the Company's independent registered public accounting firm and the appointment of PricewaterhouseCoopers LLP as the successor auditor, both approved by the Audit Committee on June 10, 2026. This is a classic auditor change under Item 4.01, and is material because it affects the registrant's financial reporting oversight and audit quality assurance.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.
View raw filing on EDGAR →Intuit issued $1.75 billion in aggregate principal amount of senior notes ($750M due 2031 at 4.950% and $1B due 2036 at 5.500%), with net proceeds of approximately $1.74 billion intended for general corporate purposes including potential refinancing of existing debt. While this is a material financing event affecting the registrant's capital structure and liquidity, it does not fit cleanly into the more specific event categories (not a dilutive equity issuance, not M&A activity, not a covenant breach or going-concern disclosure). The disclosure is routine debt issuance disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →This Item 5.07 discloses the results of the Company's June 9, 2026 annual meeting of shareholders, including voting outcomes on three matters: (1) election of six trustees, where all candidates failed to meet the two-thirds vote requirement but will continue in office under Maryland law; (2) ratification of Deloitte & Touche LLP as independent auditor, which passed; and (3) an advisory say-on-pay resolution that was rejected by shareholders. The disclosure of shareholder vote results, particularly the failure of the say-on-pay proposal and the trustee election shortfall, is material to investors assessing governance and compensation practices.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fractyl Health's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Marc Elia, Clive Meanwell, and Ian Sheffield), and (2) ratification of Ernst & Young LLP as independent auditors. All matters were approved. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →Seagate announced a redemption of $1 billion in 3.50% Exchangeable Senior Notes due 2028, with a redemption date of September 8, 2026. This debt management action affects the company's capital structure and involves convertible debt that may result in shareholder dilution through the exchange mechanism.
View raw filing on EDGAR →The filing discloses J. W. Mays, Inc.'s financial results for the three and nine months ended April 30, 2026, including revenues and net loss figures with year-over-year comparisons. A press release reporting quarterly financial results is the classic earnings_release event, and Item 2.02 is the standard disclosure location for such announcements.
View raw filing on EDGAR →The registrant announced a second quarter cash dividend of $0.45 per share via press release on June 11, 2026. While dividend declarations are routine for REITs like Chimera Investment Corp, they are material to investors as they directly affect shareholder returns and are a key metric for evaluating the company's financial health and distribution capacity. This does not fit the earnings_release category (which typically discloses quarterly/annual financial results) but represents a material capital allocation decision.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Chimera Investment Corp's June 10, 2026 annual meeting of stockholders. The filing presents detailed vote tallies for three proposals: election of three Class I Directors (Kevin G. Chavers, Gerard Creagh, and Susan Mills), a non-binding advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a textbook shareholder_vote_results event.
View raw filing on EDGAR →The filing explicitly discloses an earnings release announcing "results of operations for the fiscal quarter ended April 30, 2026," distributed via wire service and posted to the company's investor relations website. The earnings release is furnished as Exhibit 99.1 under Item 2.02 of Form 8-K, which is the standard Item for quarterly financial results disclosure.
View raw filing on EDGAR →The Board approved the appointment of Yiftach Kleinman as Chief Executive Officer, effective no later than September 8, 2026, with a base salary of NIS 80,000/month, bonus structure, and an equity grant of 53,600 options. Mr. Balucka was relieved from the CEO role as part of this leadership transition.
View raw filing on EDGAR →This Item 5.07 discloses the results of Triller Group Inc.'s 2025 annual meeting of shareholders held on June 10, 2026, including voting outcomes on six proposals: election of four directors, ratification of auditors, approval of a reverse stock split (up to 1-for-10), approval of a name change to "Eight Holdings Inc.," approval of a 2026 Equity Incentive Plan with 39.6 million shares reserved, and approval of a PIPE financing of up to $300 million. The shareholder votes on the reverse split, name change, equity plan, and dilutive PIPE financing are material to investors' assessment of the company's capital structure and strategic direction.
View raw filing on EDGAR →Adial Pharmaceuticals completed the acquisition of Azora Therapeutics on June 11, 2026 pursuant to a two-step merger agreement, with Azora becoming a wholly owned subsidiary. Azora stockholders received 437,474 shares of Common Stock and 12,930.617 shares of Series A Preferred Stock, resulting in Azora equityholders holding approximately 86.9% of outstanding shares on a fully diluted basis, constituting a change of control requiring Nasdaq approval.
View raw filing on EDGAR →In connection with the Azora acquisition, Adial issued 437,474 shares of Common Stock, 12,930,617 shares of Series A Preferred Stock convertible into common shares, and warrants exercisable for up to 35,342,844 shares of Common Stock, all issued pursuant to the Merger Agreement and financing arrangements in reliance on Section 4(a)(2) exemption.
View raw filing on EDGAR →Matt Davidson, Ph.D. was appointed as Chief Development Officer and Class I Director, and Wendy B. Young, Ph.D. was appointed as Class III Director, both effective immediately upon closing of the Azora merger on June 11, 2026.
View raw filing on EDGAR →Adial Pharmaceuticals guaranteed the Azora Notes upon closing of the merger, creating a direct financial obligation that arises from the material acquisition transaction.
View raw filing on EDGAR →The filing discloses the appointment of Roy Cohen as Chief Financial Officer, effective June 1, 2026. The principal action is a person taking a role—a named executive officer position. While compensation terms are disclosed (NIS 55,000–65,000 per month), the core event is the appointment itself, not a compensation arrangement. CFO appointments are material to investors as they affect financial reporting oversight and corporate governance.
View raw filing on EDGAR →The Board postponed the 2026 Annual Meeting scheduled for June 18, 2026, citing a need for "additional time to evaluate certain matters relating to the Annual Meeting and the business to be presented to stockholders." While the disclosure does not specify the underlying issues, the vague language about evaluating "certain matters" relating to both the meeting and business operations, combined with the decision to postpone without a rescheduled date, suggests potential material concerns that do not fit neatly into standard event categories. This is material to investors as it signals unspecified governance or operational issues requiring investigation.
View raw filing on EDGAR →The filing discloses the removal of Christodoulos Tzoutzakis as Chief Operating Officer and Chief Technology Officer, effective June 11, 2026. This is a departure of a named executive officer from material positions. Although the Board explicitly states the removal was "without cause" and not due to disagreement or operational issues, the principal disclosed action is a person leaving executive roles, which is the defining characteristic of exec_departure.
View raw filing on EDGAR →